OBJECTIVE: To address the independent roles of peptidylarginine deiminase type 2 (PAD2) and PAD4 in generating rheumatoid arthritis (RA) autoantigens by using a system that mimics intracellular citrullination in the RA joint. METHODS: PAD2- or PAD4-expressing 293T cells and mock-transfected cells were used as targets in cytotoxic assays using lymphokine-activated killer cells, cytotoxic YT cell granule contents, or purified human perforin. Protein citrullination and autoantigen production were determined by immunoblotting using the anti-modified citrulline-Senshu method and RA sera (n = 30), respectively. RESULTS: RA sera recognized at least 3 categories of autoantigens in PAD-expressing target cells killed by the cytotoxic lymphocyte granule-induced death pathway. These included: 1) autoantigens targeted in their native form, 2) citrullinated antigens, and 3) antigens cleaved by cytotoxic proteases (e.g., granzymes). Interestingly, although target cells expressing PAD2 or PAD4 showed prominent hypercitrullination of a broad range of proteins during cytotoxic granule-induced cell damage, autoantibodies in RA sera targeted only a very limited number of antigens in hypercitrullinated cells. Furthermore, RA sera showed distinct reactivities to autoantigens generated by PAD2 or PAD4. CONCLUSION: The cytotoxic granule-induced death pathway has the capacity to modify antigens by inducing hypercitrullination and antigen cleavage in target cells. Interestingly, among a large number of citrullinated proteins generated by PAD2 and PAD4 in cells, only a few are likely involved in the production of autoantibodies in RA.
OBJECTIVE: To address the independent roles of peptidylarginine deiminase type 2 (PAD2) and PAD4 in generating rheumatoid arthritis (RA) autoantigens by using a system that mimics intracellular citrullination in the RA joint. METHODS:PAD2- or PAD4-expressing 293T cells and mock-transfected cells were used as targets in cytotoxic assays using lymphokine-activated killer cells, cytotoxic YT cell granule contents, or purified human perforin. Protein citrullination and autoantigen production were determined by immunoblotting using the anti-modified citrulline-Senshu method and RA sera (n = 30), respectively. RESULTS:RA sera recognized at least 3 categories of autoantigens in PAD-expressing target cells killed by the cytotoxic lymphocyte granule-induced death pathway. These included: 1) autoantigens targeted in their native form, 2) citrullinated antigens, and 3) antigens cleaved by cytotoxic proteases (e.g., granzymes). Interestingly, although target cells expressing PAD2 or PAD4 showed prominent hypercitrullination of a broad range of proteins during cytotoxic granule-induced cell damage, autoantibodies in RA sera targeted only a very limited number of antigens in hypercitrullinated cells. Furthermore, RA sera showed distinct reactivities to autoantigens generated by PAD2 or PAD4. CONCLUSION: The cytotoxic granule-induced death pathway has the capacity to modify antigens by inducing hypercitrullination and antigen cleavage in target cells. Interestingly, among a large number of citrullinated proteins generated by PAD2 and PAD4 in cells, only a few are likely involved in the production of autoantibodies in RA.
Authors: Maximilian F Konig; Loreto Abusleme; Jesper Reinholdt; Robert J Palmer; Ricardo P Teles; Kevon Sampson; Antony Rosen; Peter A Nigrovic; Jeremy Sokolove; Jon T Giles; Niki M Moutsopoulos; Felipe Andrade Journal: Sci Transl Med Date: 2016-12-14 Impact factor: 17.956
Authors: Erika Darrah; AeRyon Kim; Xi Zhang; Tatiana Boronina; Robert N Cole; Andrea Fava; Jon T Giles; Clifton O Bingham III; Michael J Chalmers; Patrick R Griffin; Scheherazade Sadegh-Nasseri; Antony Rosen Journal: J Proteome Res Date: 2016-10-20 Impact factor: 4.466
Authors: Johanna Steen; Björn Forsström; Peter Sahlström; Victoria Odowd; Lena Israelsson; Akilan Krishnamurthy; Sara Badreh; Linda Mathsson Alm; Joanne Compson; Daniel Ramsköld; Welcome Ndlovu; Stephen Rapecki; Monika Hansson; Philip J Titcombe; Holger Bang; Daniel L Mueller; Anca I Catrina; Caroline Grönwall; Karl Skriner; Peter Nilsson; Daniel Lightwood; Lars Klareskog; Vivianne Malmström Journal: Arthritis Rheumatol Date: 2019-02 Impact factor: 10.995
Authors: Dres Damgaard; Mads Emil Bjørn; Maria A Steffensen; Ger J M Pruijn; Claus H Nielsen Journal: Arthritis Res Ther Date: 2016-05-05 Impact factor: 5.156
Authors: Dres Damgaard; Mandar Bawadekar; Ladislav Senolt; Allan Stensballe; Miriam A Shelef; Claus H Nielsen Journal: PLoS One Date: 2018-08-30 Impact factor: 3.240
Authors: Yebin Zhou; Bo Chen; Nanette Mittereder; Raghothama Chaerkady; Martin Strain; Ling-Ling An; Saifur Rahman; Wenting Ma; Choon Pei Low; Denice Chan; Frances Neal; Clifton O Bingham; Kevon Sampson; Erika Darrah; Richard M Siegel; Sarfaraz Hasni; Felipe Andrade; Katherine A Vousden; Tomas Mustelin; Gary P Sims Journal: Front Immunol Date: 2017-09-25 Impact factor: 8.786
Authors: Katharine B Moosic; Kusuma Ananth; Felipe Andrade; David J Feith; Erika Darrah; Thomas P Loughran Journal: Front Oncol Date: 2022-05-13 Impact factor: 5.738